SAN
JOSE, Calif., March 3,
2025 /PRNewswire/ -- Biosciences, Inc. ("Anixa"
or the "Company") (NASDAQ: ANIX), a biotechnology company focused
on the treatment and prevention of cancer, today announced Dr.
Pam Garzone, Chief Development
Officer of Anixa, will be attending the Alliance for Cancer Gene
Therapy (ACGT) Summit 2025 and participating as a panelist on the
Gynecologic and Breast Cancers panel. The Alliance for Cancer Gene
Therapy Summit 2025 is being held on Wednesday and Thursday, March 19 - 20, 2025, at the Alexandria
Center for Life Science in New York
City.
Dr. Garzone will join leading experts in the field to discuss
advancements in cell and gene therapy, including Anixa's CAR-T
therapy for ovarian cancer, and its potential impact on gynecologic
and breast cancers. The panel is scheduled for Wednesday, March 19, 2025, from 11:15 AM – 12:15 PM
ET.
Dr. Amit Kumar, Chairman and CEO
of Anixa, stated, "We are pleased that Anixa and Dr. Garzone were
invited to share insights at the ACGT Summit. Our discussions and
contributions to the development of novel cancer therapies will
help drive meaningful discussions on the future of gene-based
treatments for gynecologic and breast cancers."
The Alliance for Cancer Gene Therapy Summit 2025 will bring
together leading physician scientists advancing research to develop
curative cell and gene therapies for solid tumor cancers.
For more information about the conference, visit Alliance for
Gene Therapy Summit 2025.
About Anixa Biosciences, Inc.
Anixa is a
clinical-stage biotechnology company focused on the treatment and
prevention of cancer. Anixa's therapeutic portfolio consists of an
ovarian cancer immunotherapy program being developed in
collaboration with Moffitt Cancer Center, which uses a novel type
of CAR-T, known as chimeric endocrine receptor-T cell (CER-T)
technology. The Company's vaccine portfolio includes vaccines being
developed in collaboration with Cleveland Clinic to treat and
prevent breast cancer and ovarian cancer, as well as additional
cancer vaccines to address many intractable cancers, including high
incidence malignancies in lung, colon, and prostate. These vaccine
technologies focus on immunizing against "retired" proteins that
have been found to be expressed in certain forms of cancer. Anixa's
unique business model of partnering with world-renowned research
institutions on all stages of development allows the Company to
continually examine emerging technologies in complementary fields
for further development and commercialization. To learn more, visit
www.anixa.com or follow Anixa on Twitter, LinkedIn, Facebook
and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements are not statements of historical facts, but rather
reflect Anixa's current expectations concerning future events and
results. We generally use the words "believes," "expects,"
"intends," "plans," "anticipates," "likely," "will" and similar
expressions to identify forward-looking statements. Such
forward-looking statements, including those concerning our
expectations, involve risks, uncertainties and other factors, some
of which are beyond our control, which may cause our actual
results, performance or achievements, or industry results, to be
materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. These risks, uncertainties and factors include, but are
not limited to, those factors set forth in "Item 1A - Risk Factors"
and other sections of our most recent Annual Report on Form 10-K as
well as in our Quarterly Reports on Form 10-Q and Current Reports
on Form 8-K. We undertake no obligation to publicly update or
revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by law.
You are cautioned not to unduly rely on such forward-looking
statements when evaluating the information presented in this press
release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download
multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-chief-development-officer-dr-pam-garzone-to-speak-at-the-alliance-for-cancer-gene-therapy-summit-2025-on-march-19th-302389363.html
SOURCE Anixa Biosciences, Inc.
